Vienna, Austria- May 7 2009- Nabriva Therapeutics, a biotechnology company focused on developing a new class of antibiotics for the treatment of serious infections caused by resistant pathogens, has announced the appointment of George H. Talbot, M.D. to its Supervisory Board.
Dr. Talbot is highly respected in the field of anti-infective drug development and has contributed to the development of many marketed and investigational antimicrobials. He began his pharmaceutical career at Rhone-Poulenc Rorer, assuming positions of increasing responsibility as the company evolved into Aventis Pharmaceuticals. From June 2006 until October 2007, Dr. Talbot served as Executive Vice President and Chief Medical Officer of Cerexa, Inc. Cerexa, which specializes in anti-bacterial drug development, was purchased by Forest Laboratories in January 2007.
Dr. Talbot commented, “Nabriva is one of the most promising anti-infective companies out there, and so I am delighted to have been invited to join the Supervisory Board. I am particularly excited by the potential of Nabriva’s systemically administered pleuromutilins, especially now that their lead products are in the clinic.”
Dr. David Chiswell, CEO of Nabriva Therapeutics said: “We are delighted to have Dr. Talbot on board. We will generate key human data in 2009 for our two lead pleuromutilin-based antibiotics BC-3205 and BC-3781, which are being developed to treat life-threatening infectious diseases caused by multi-drug resistant (MDR) pathogens including methicillin-resistant Staphylococcus aureus and MDR Streptococcus pneumoniae. Dr. Talbot’s experience in anti-infective drug development will prove invaluable as we continue the clinical development of these molecules.”
Dr. Talbot received his Bachelor of Arts degree in Religion and Psychology from Wesleyan University and his Doctorate in Medicine from the Yale University School of Medicine. He completed his training in Internal Medicine and Infectious Diseases at the University of Pennsylvania hospitals, and then assumed successive faculty positions at the University of Pennsylvania School of Medicine. While at the University of Pennsylvania, Dr. Talbot’s main research interests were the epidemiology and management of nosocomial infections, including those occurring in patients with acute leukemia, as well as clinical trials of new antimicrobial agents. Dr. Talbot currently sits on the scientific advisory boards of Calixa Therapeutics, Inc. and Actelion Pharmaceuticals. He is a fellow of the Infectious Diseases Society of America (IDSA) and a founding member of IDSA’s Antimicrobial Availability Task Force
About Nabriva Therapeutics
Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics for the treatment of serious infections caused by resistant pathogens. The Company’s two systemically available pleuromutilin antibiotics, BC-3205 and BC-3781, are being developed for both oral and IV administration with extensive clinical phase I data becoming available during 2009. In addition, Nabriva Therapeutics’ topical pleuromutilin product candidate, BC-7013, is also in clinical phase I.
Nabriva Therapeutics has a proven track record in world-class medicinal chemistry, clinical expertise, a seasoned management team and solid IP. Nabriva Therapeutics is located in Vienna, Austria.
For more information on Nabriva please visit www.nabriva.com.
